2,880 results on '"Dingli, David"'
Search Results
2. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
3. Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
4. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
5. Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study
6. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
7. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
8. Mode of progression in smoldering multiple myeloma: a study of 406 patients
9. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
10. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
11. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
12. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
13. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
14. Muscle and fat composition in patients with newly diagnosed multiple myeloma
15. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
16. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
17. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
18. ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
19. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
20. Conditional survival in multiple myeloma and impact of prognostic factors over time
21. Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
22. Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape
23. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
24. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
25. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.
26. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
27. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
28. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
29. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
30. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
31. Outcomes after biochemical or clinical progression in patients with multiple myeloma
32. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
33. Metformin and cytokine release syndrome after immune effector cell therapy.
34. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.
35. First relapse in patients with multiple myeloma: Outcomes and predictors.
36. Class comparison of BCMA-directed therapies in relapsed multiple myeloma.
37. Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
38. The Impact of Pharmacogenomic CYP3A5 Variants on Calcineurin Inhibitor Metabolism and SLCO1B1 Variants on Methotrexate in Adult Allogeneic BMT Patients
39. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
40. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
41. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant
42. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
43. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
44. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
45. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
46. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
47. Kidney Transplant Outcomes of Patients With Multiple Myeloma
48. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system.
49. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
50. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.